NASDAQ:MITO Stealth BioTherapeutics (MITO) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free MITO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.32▼$0.3250-Day Range$0.31▼$0.3252-Week Range$0.16▼$1.03VolumeN/AAverage Volume946,105 shsMarket Capitalization$23.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Stealth BioTherapeutics alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Stealth BioTherapeutics Stock (NASDAQ:MITO)Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. MITO Stock News HeadlinesApril 17, 2024 | money.usnews.comBolt Biotherapeutics IncApril 8, 2024 | prnewswire.comSTEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROMEApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 22, 2024 | wsj.comSonnet BioTherapeutics Holdings Inc.February 9, 2024 | investing.comIovance Biotherapeutics Inc (IOVA)November 23, 2023 | morningstar.comBarinthus Biotherapeutics PLC ADR BRNSNovember 17, 2023 | bizjournals.comLab Notes: Vittoria Biotherapeutics raises $15M; Madrigal adds to C-suiteNovember 16, 2023 | morningstar.comIovance Biotherapeutics Inc IOVAApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.November 9, 2023 | morningstar.comSAB Biotherapeutics Inc SABSOctober 30, 2023 | investing.comCalidi Biotherapeutics Inc (CLDI)September 12, 2023 | msn.comStealth BioTherapeutics achieves target enrolment in PMM therapy trialSeptember 11, 2023 | benzinga.comStealth BioTherapeutics Completes Target Enrollment in Global Phase 3 NuPOWER Trial in Patients with Primary Mitochondrial MyopathySeptember 6, 2023 | bizjournals.comAs Needham biotech struggles with FDA, patients with an ultra-rare disease are waitingJune 2, 2023 | news.yahoo.comB-2 stealth bombers to return to flight after 5-month delayMay 16, 2023 | dailymail.co.ukWealth with stealthMarch 27, 2023 | marketwatch.comGlobal Mitochondrial Myopathy Diagnosis & Treatment Market Size by Type (itochondrial Myopathy Diagnosis) Forecast from 2023 to 2028February 25, 2023 | techcrunch.comChain Reaction raises $70M, emerges from stealth to launch chips designed to compute encrypted dataFebruary 19, 2023 | finance.yahoo.comWill Roper's Istari, Inc. emerges from stealth mode to transform digital engineering and accelerate Industry 4.0November 16, 2022 | finance.yahoo.comStealth BioTherapeutics Corp Announces Completion of MergerNovember 1, 2022 | finance.yahoo.comStealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)October 27, 2022 | news.yahoo.comAs Trump Org trial looms, lawyers to look out for 'stealth jurors'October 7, 2022 | finance.yahoo.comStealth BioTherapeutics Corp to Hold Extraordinary General Meeting of ShareholdersSeptember 15, 2022 | finance.yahoo.comStealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease EventsAugust 5, 2022 | msn.comShort Volatility Alert: Stealth BioTherapeutics CorpAugust 1, 2022 | benzinga.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Stealth BioTherapeutics Corp (Nasdaq - MITO), Romeo Power, Inc. (NYSE - RMO), One Medical (Nasdaq - ONEM), Hanger, Inc. (NYSE - HNGR)August 1, 2022 | nasdaq.comStealth BioTherapeutics To Be Taken Private In All-cash DealSee More Headlines Receive MITO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MITO CUSIPN/A CIK1696396 Webwww.stealthbt.com Phone617-600-6888FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-142.81% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual Sales$21.09 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.79) per share Price / Book-0.41Miscellaneous Outstanding Shares73,552,000Free FloatN/AMarket Cap$23.54 million OptionableNot Optionable Beta1.46 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Irene P. McCarthy J.D. (Age 57)Pres ,CEO, Sec. & Director Mr. Henry HessChief Legal CounselDr. Ben R. Bronstein M.D. (Age 72)Chief Medical Officer Mr. Brian HotchkissVP of Bus. Devel. & StrategyKey CompetitorsOncternal TherapeuticsNASDAQ:ONCTCytoMed TherapeuticsNASDAQ:GDTCCumberland PharmaceuticalsNASDAQ:CPIXBiora TherapeuticsNASDAQ:BIORBullfrog AINASDAQ:BFRGView All Competitors MITO Stock Analysis - Frequently Asked Questions How were Stealth BioTherapeutics' earnings last quarter? Stealth BioTherapeutics Corp (NASDAQ:MITO) posted its earnings results on Thursday, August, 5th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. What other stocks do shareholders of Stealth BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), Soleno Therapeutics (SLNO) and Arbutus Biopharma (ABUS). When did Stealth BioTherapeutics IPO? Stealth BioTherapeutics (MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager. This page (NASDAQ:MITO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stealth BioTherapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
